At a glance
This week, ClinicalTrials.gov registered 1,031 new clinical trials while 4,402 existing studies posted status updates — reflecting protocol amendments, enrollment completions, or results filings. Across all active studies, 2,316 trials (43%) are currently recruiting patients, and 887 are in pre-enrollment, not yet recruiting.
Phase distribution
Early-stage research continues to dominate the registry, with Phase 1 and 2 studies making up the bulk of new and updated activity. Phase 3 confirmatory trials — the studies closest to potential approval — represent the highest-value intelligence for competitive monitoring: these are the programs that define the near-term pipeline.
| Phase | Trials | Share |
|---|---|---|
| N/A | 1,865 | |
| Not specified | 1,236 | |
| Phase 2 | 745 | |
| Phase 3 | 530 | |
| Phase 1 | 501 | |
| Phase 1 / Phase 2 | 244 | |
| Phase 4 | 164 | |
| Phase 2 / Phase 3 | 92 |
Industry: who filed the most trials this week?
Among sponsor-initiated (industry) trials updated this week, the top pharma and biotech companies by trial volume give a real-time view of where R&D resources are concentrated. High volume from a single sponsor often signals a broad platform strategy — multiple indications, combinations, or geographies for a core asset.
| # | Sponsor | Trials |
|---|---|---|
| 1 | AstraZeneca | 67 |
| 2 | Merck Sharp & Dohme LLC | 58 |
| 3 | Eli Lilly and Company | 52 |
| 4 | Boehringer Ingelheim | 49 |
| 5 | Novartis Pharmaceuticals | 48 |
| 6 | Pfizer | 44 |
| 7 | Bayer | 27 |
| 8 | Sanofi | 25 |
Therapeutic area breakdown
Oncology's dominance of the clinical trial landscape is a structural feature of modern drug development, not a weekly fluctuation. The FDA's breakthrough therapy designation and accelerated approval pathways have made cancer one of the most commercially attractive areas in biopharma. Neurology and immunology are the other perennial high-activity areas, reflecting large unmet needs and biologic platform opportunities.
Never miss a trial in your area
DataLookout sends you a weekly digest of new and updated trials matching your disease area or competitor. Free forever for one tracker.
Set Up Your Free AlertNo credit card. No sales call. Just the trials that matter to you. [email protected]
Notable Phase 3 trials recruiting now
These are industry-sponsored Phase 3 trials that are actively enrolling patients and were posted or updated this week. Phase 3 studies represent confirmed commercial intent — a company has committed to pivotal trial infrastructure and is ready to put its asset in front of regulators.
A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)
Anemia Due to Chronic Kidney Disease
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity
Upper Limb Spasticity
ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets (+1 more)
Bacterial Reduction for a Manual Toothbrush With a 360-Degree Mouth Cleaner Design Versus a Standard Toothbrush
Bacterial Load Reduction
Clinical Study to Assess the Efficacy of New Toothpaste Containing SnF as Compared to Colgate Cavity Protection Toothpaste on the Reduction of Enamel Erosion
Enamel Erosion
Source: ClinicalTrials.gov. Trials filtered to Industry sponsor, RECRUITING status, Phase 3 designation, updated within the past 7 days. Browse all trials →
How to use this data
The weekly trial activity report is useful context, but the real value for competitive intelligence comes from targeted monitoring: knowing when a specific competitor files a new trial in your indication, or when a Phase 2 you've been tracking advances to Phase 3.
That's what DataLookout is built for. You tell us which disease areas or sponsors to watch, and we send you a digest the moment something relevant changes. Free tier covers one tracker with weekly delivery. Paid plans unlock daily alerts and multiple trackers.
Get this report — and more — in your inbox
Subscribe to DataLookout for weekly (or daily) clinical trial alerts personalized to your therapeutic area. Built for pharma, biotech, and life sciences professionals who need to stay current without the noise.
Start Monitoring for Free